Xiaoming Zhao

Xiaoming Zhao

Auto-generated profile, based on publicly available information

Xiaoming Zhao

Scientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, 130033, China

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2012 in Reproductive BioMedicine Online
Verified
Journal Article
Open access
PDF file
XCXinyue Chang
Xinyue Chang
YQYingying Qin
Yingying Qin
CXChengyan Xu
Chengyan Xu
GLGuangyu Li
Guangyu Li
XZXiaoming Zhao
Xiaoming Zhao
CZChen Zi-Jiang
Chen Zi-Jiang
It is known that Müllerian ducts develop into the upper two-thirds of the vagina, uterus and Fallopian tubes ( Varner et al., 1985 x Varner et al., 1985 Varner, R.E., Younger, J.B., and Blackwell, R.E. Mullerian dysgenesis. J. Reprod. Med. 1985; 30: 443–450 PubMed | Google Scholar See all References Varner et al., 1985 ) and any alteration in the developmental sequence would lead to a wide spectrum of female reproductive tract abnormalities, called Müllerian duct abnormalities (MDA). The clinical presentation of MDA varies including congenital vagina and uterus defect (Mayer-Rokitansky–Küster–Hauser (MRKH) syndrome; Griffin et al., 1976 x Griffin et al., 1976 Griffin, J.E., Edwards, C., Madden, J.D., Harrod, M.J., and Wilson, J.D. Congenital absence of the vagina: The Mayer–Rokitansky–Kuster–Hauser syndrome. Ann. Intern. Med. 1976; 85: 224–236 Crossref | PubMed | Scopus (253) | Google Scholar See all References Griffin et al., 1976 ), uterine agenesis, unicornuate uterus, didelphic uterus, bicornuate uterus, septate uterus and vaginal septum ( Creatsas et al., 2010 x Creatsas et al., 2010 Creatsas, G., Deligeoroglou, E., and Christopoulos, P. Creation of a neovagina after Creatsas modification of Williams vaginoplasty for the treatment of 200 patients with Mayer–Rokitansky–Kuster-Hauser syndrome. Fertil. Steril. 2010; 94: 1848–1852 Abstract | Full Text | Full Text PDF | PubMed | Scopus (29) | Google Scholar See all References , Parelkar et al., 2009 x Parelkar et al., 2009 Parelkar, S.V., Gupta, R.K., Oak, S., Sanghvi, B., Kaltari, D., Patil, R.S., Prakash, A., and Shimoga, P. Laparoscopic management of persistent mullerian duct syndrome. J. Pediatr. Surg. 2009; 44: e1–e3 Abstract | Full Text | Full Text PDF | PubMed | Scopus (14) | Google Scholar See all References , Tiker et al., 2000 x Tiker et al., 2000 Tiker, F., Yildirim, S.V., Barutcu, O., and Bagis, T. Familial mullerian agenesis. Turk. J. Pediatr. 2000; 42: 322–324 PubMed | Google Scholar See all References ). It is often accompanied with other somatic malformations, such as renal agenesis (25%), skeletal anomalies (10–12%) and, more rarely, cardiac or middle ear anomalies ( Morcel et al., 2007 x Morcel et al., 2007 Morcel, K., Camborieux, L., and Guerrier, D. Mayer–Rokitansky–Küster–Hauser (MRKH) syndrome. Orp. J. Rare Dise. 2007; 2: 13 Crossref | PubMed | Scopus (186) | Google Scholar See all References Morcel et al., 2007 ). Patients with MDA are asymptomatic before preadolescence and would not be diagnosed with a uterine defect until the child-bearing period because of infertility, recurrent spontaneous abortion, premature birth, abnormal fetal presentation or cyclic pain ( Bernardini et al., 2009 x Bernardini et al., 2009 Bernardini, L., Gimelli, S., Gervasini, C., Carella, M., Baban, A., Frontino, G., Barbano, G., Divizia, T.M., Fedele, L., Novelli, A., Bena, F., Lalatta, F., Miozzo, M., and Dallapiccola, B. Recurrent microdeletion at 17q12 as a cause of Mayer-Rokitansky–Kuster-Hauser (MRKH) syndrome: two case reports. Orphanet J. Rare Dis. 2009; 4: 25 Crossref | PubMed | Scopus (71) | Google Scholar See all References , Biason et al., 2007 x Biason et al., 2007 Biason, L.A., De Filippo, G., Konrad, D., Scarano, G., Nazzaro, A., and Schoenle, E.J. WNT4 deficiency-a clinical phenotype distinct from the classic Mayer-Rokitansky–Kuster-Hauser syndrome: a case report. Hum. Reprod. 2007; 22: 224–229 Crossref | PubMed | Scopus (103) | Google Scholar See all References , Sadic et al., 2002 x Sadic et al., 2002 Sadic, S., Taskin, O., Sehirali, S., Mendilcioglu, I., önoglu, A.S., Kursun, S., and Wheeler, M.J. Complex mullerian malformation: report of a case with a hypoplartic non-carvitated uterus and two rudimentary horns. Hum. Reprod. 2002; 17: 1343–1344 Crossref | PubMed | Google Scholar See all References ). The incidence of MDA in infertile women is about 5% ( Nik-Zainal et al., 2011 x Nik-Zainal et al., 2011 Nik-Zainal, S., Strick, R., Storer, M., Huang, N., Rad, R., Willatt, L., Fitzgerald, T., Martin, V., Sandford, R., Carter, N.P., Janecke, A.R., Renner, S.P., Oppelt, P.G., Oppelt, P., Schulze, C., Brucker, S., Hurles, M., Beckmann, M.W., Strissel, P.L., and Shaw-Smith, C. High incidence of recurrent copy number variants in patients with isolated and syndromic Müllerian aplasia. J. Med. Genet. 2011; 48: 197–204 Crossref | PubMed | Scopus (56) | Google Scholar See all References Nik-Zainal et al., 2011 ).

30 July 2015 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
PDF file
MGMinzhi Gao
Minzhi Gao
YSYun Sun
Yun Sun
HXHuiliang Xie
Huiliang Xie
SFSuping Fang
Suping Fang
XZXiaoming Zhao
Xiaoming Zhao

14 December 1999 in Circulation
Verified
Journal Article
Open access
PDF file
GMGeraldine G. Miller
Geraldine G. Miller
SDStacy F. Davis
Stacy F. Davis
JAJames B. Atkinson
James B. Atkinson
DCDonald B. Chomsky
Donald B. Chomsky
PPPedro Pedroso
Pedro Pedroso
RPRichard N. Pierson
Richard N. Pierson
Background —Vascular smooth muscle cell growth factors are postulated to contribute to cardiac allograft vasculopathy (CAV). Few data quantitatively address the timing, location, or stimuli for growth factor expression and relationship to CAV. Methods and Results —Acidic fibroblast growth factor (aFGF) mRNA expression was determined in serial endomyocardial biopsies during the first year after transplantation. Patients with high levels of aFGF mRNA and elevations after the early posttransplant period had significantly more severe CAV than patients with low aFGF and no late elevations. Conclusions —Parenchymal aFGF expression varies between patients and in the same patient over time and correlates with development of CAV.

1 January 2025 in Biomaterials Research
Verified
Journal Article
Open access
ALAnran Li
Anran Li
CCCong Chen
Cong Chen
TZTongjia Zhang
Tongjia Zhang
YTYuxin Tian
Yuxin Tian
YCYifan Cao
Yifan Cao
LWLiping Wang
Liping Wang
Human umbilical cord mesenchymal stem cell extracellular vesicles (hucMSC-EVs) exhibit remarkable potential for alleviating type 2 diabetes mellitus (T2DM). However, the role of hucMSC-EVs in T2DM, particularly concerning oxidative damage to pancreatic β cells, remains underexplored. This study utilized a high-fat diet and streptozotocin (STZ)-induced T2DM mouse model and an STZ-induced INS-1 cell damage model to investigate the effects and mechanisms of hucMSC-EVs. In the T2DM mouse model, hucMSC-EVs effectively lowered blood glucose levels, improved lipid metabolism disorders, and preserved liver function. Moreover, hucMSC-EVs enhanced insulin sensitivity and mitigated oxidative damage. Histological analysis confirmed that hucMSC-EVs marked alleviated liver, kidney, and pancreatic tissue damage. In vitro studies demonstrate that hucMSC-EVs enhance glucose absorption and glycogen synthesis in an insulin-resistant HepG2 model and stimulated insulin secretion in INS-1 cells under high-glucose conditions. In the STZ-induced INS-1 oxidative damage model, hucMSC-EVs protect against oxidative damage by increasing antioxidant enzyme activities, reducing reactive oxygen species production, and decreasing cell apoptosis. The effects were partially mediated by the activation of the phosphatidylinositol 3-kinase (PI3K)/AKT and signal transducer and activator of transcription (STAT) signaling pathways, as well as the up-regulation of key antioxidant proteins such as Nrf2, SOD1, and Bcl2. Further research revealed that miR-191-5p, which is enriched in hucMSC-EVs, targets DAPK1 to activate the PI3K/AKT pathway, thereby contributing to the protective effects against oxidative damage. These findings highlight the critical role and underlying mechanisms of hucMSC-EVs in ameliorating metabolic dysfunction in T2DM, particularly the protective effects against oxidative damage, thus providing a novel strategy for the treatment of T2DM.

16 July 2025 in Materials Today Bio
Verified
Journal Article
Open access
XZXiaoming Zhao
Xiaoming Zhao
CKChenfei Kong
Chenfei Kong
XXXue Xia
Xue Xia
KZKelin Zhao
Kelin Zhao
MHMiao Hao
Miao Hao
JJJinlan Jiang
Jinlan Jiang
Pulmonary fibrosis (PF) is a chronic lung disease characterized by progressive fibrosis and scar tissue formation, often leading to respiratory failure. Current treatments are limited to alleviating symptoms and slowing disease progression. Mesenchymal stem cells (MSC) can be applied to treat PF owing to their anti-inflammatory, immunomodulatory, tissue repair, and vascular regeneration properties. However, the short pulmonary retention time of intravenously injected MSC limits therapeutic efficacy. We combined MSC with Fe3O4-polydopamine (Fe3O4@PDA) nanoparticles and applied an external magnetic field to guide magnetized MSC to damaged lung areas. This strategy not only enhances MSC localization, targeting, and retention but also amplifies their therapeutic effects by activating critical therapeutic molecules involved in MSC migration, adhesion, homing, and intercellular connections, as well as signaling pathways such as MAPK/AKT. In vivo studies using a PF mouse model demonstrated that Fe3O4@PDA-magnetized MSC therapy effectively alleviated lung tissue fibrosis and significantly reduced the expression of inflammatory factors. RNA sequencing analysis revealed profound changes in gene expression profiles, particularly in pathways such as ECM-receptor interactions, focal adhesion, and the TGF-β pathway. Compared to non-magnetized MSC therapy, magnetized MSC therapy significantly activated essential signaling pathways in lung tissues, including cell adhesion molecules, leukocyte transendothelial migration, and the Rap1 signaling pathway. Thus, Fe3O4@PDA-magnetized MSC therapy offers a promising strategy for optimizing MSC distribution and therapeutic molecule expression in PF treatment, paving the way for broader MSC-based applications.